Know Cancer

or
forgot password

Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients


N/A
18 Years
N/A
Not Enrolling
Female
Breast Neoplasms

Thank you

Trial Information

Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients


Inclusion Criteria:



Inclusion Criteria - Stage IV breast cancer patients

1. Patient age must be > 21 years.

2. Patient must have a tissue diagnosis of invasive breast cancer.

3. Patient must have documented evidence of metastatic disease.

4. Patient must have measurable lesions.

5. Patients must be initiating systemic therapy. Patients receiving hormonal therapy,
and/or chemotherapy alone or in combination with other therapies are eligible.

6. Patient must have an ECOG performance status of 0, 1, or 2.

7. Patient must be available for follow-up.

8. Patient or their authorized legally acceptable representative must consent to be in
the study and must have signed and dated an approved consent form which conforms to
federal and institutional guidelines.

9. The patient with a previous history of non-breast malignancy is eligible for this
study only if the patient meets the following criteria for a cancer survivor. A
cancer survivor is eligible provided the following criteria are met: (1) patient has
undergone potentially curative therapy for all prior malignancies, (2) patients have
been considered disease free for at least 5 years (with the exception of basal cell
or squamous cell carcinoma of the skin or carcinoma-in-situ of the cervix).

Inclusion Criteria - Healthy volunteers

A volunteer will be eligible for inclusion in this study only if ALL of the following
criteria apply:

1. Volunteer age must be > 21 years.

2. Volunteer or their authorized legally acceptable representative must consent to be in
the study and must have signed and dated an approved consent form which conforms to
federal and institutional guidelines.

3. Patients with benign breast disease are eligible for enrollment.

4. The volunteer with a previous history of non-breast malignancy is eligible for this
study only if the patient meets the following criteria for a cancer survivor. A
cancer survivor is eligible provided both of the following criteria are met: (1)
patient has undergone potentially curative therapy for all prior malignancies, (2)
patient has been considered disease free for at least 5 years (with the exception of
basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the
cervix).

Exclusion Criteria:

Exclusion Criteria - Stage IV breast cancer patients

A patient will be ineligible for inclusion in this study if ANY of the following criteria
apply:

1. No documented metastatic disease.

2. No measurable lesions.

3. Bone only and/or brain metastasis.

4. Patient is not initiating a new regimen of systemic therapy.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Outcome Measure:

The prevalence of breast cancer cells in the peripheral blood

Outcome Description:

Specifically, it is predicted that 60% of subjects with Stage IV breast cancer will have evidence of breast cancer cells in the peripheral blood by multi-marker real-time RT-PCR analysis, and that these subjects will experience a significantly decreased progression-free and overall survival.

Outcome Time Frame:

1 year

Safety Issue:

No

Principal Investigator

William E. Gillanders, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Washington University School of Medicine

Authority:

United States: Institutional Review Board

Study ID:

05-0435 / 201109033

NCT ID:

NCT00355316

Start Date:

November 2005

Completion Date:

February 2013

Related Keywords:

  • Breast Neoplasms
  • Breast Cancer
  • Peripheral
  • Blood
  • Breast Neoplasms
  • Neoplasms

Name

Location

Washington University School of MedicineSaint Louis, Missouri  63110
Medical University of South CarolinaCharleston, South Carolina  29425-0721